British Toxicological Society Annual Congress 2018 – Hilton Gateshead (16th-18th April)

British Toxicological Society Annual Congress 2018

Hilton Gateshead – 16th-18th April

The Newcells Biotech team will be attending the British Toxicological Society Annual Congress 2018 that is taking place in Gateshead on 16th-18th April.  Newcells Biotech staff will be present throughout the Congress and looking forward to engaging with the existing programme of presentations and discussions on topics such as in vitro assays, liver and lung toxicity.  Dr Mike Nicholds, Prof Lyle Armstrong and Dr Colin Brown will be attending along with a number of the Newcells technical team.

Two posters will be presented by Dr Chichagova and Dr Chung on “Using statistical models to identify key variables critical for generation of retinal organoids from iPSC for further use in pharmacological and toxicological studies”  and “Newcells Biotech’s aProximate human primary proximal tubule cell monolayers as a novel predictive model of nephrotoxicity”.

You might also be interested in…

Development of functioning in vitro lung assay for modelling Covid-19 infection

Newcells Biotech, experts in induced pluripotent stem cell (iPSC) differentiation and assay construction, have confirmed their human lung epithelium model as an effective platform for modelling SARS-CoV-2 infection and replication.  Their work alongside the Liverpool School of Tropical Medicine (LTSM) Centre for Drugs and Diagnostics will be crucial in helping

The Biosphere

Newcells Biotech scales up its operations in The Biosphere

Newcells Biotech, a pioneering life-sciences spin-out that applies Human induced Pluripotent Stem Cells (hiPSCs) to develop assays for drug development, have consolidated their two laboratory sites into 500m2 of laboratory and co-located office space in The Biosphere, which forms part of the Newcastle Helix cluster.    The purpose-built space in the city centre site

COVID-19 Vaccine

An Overview of Vaccine Development & Sub-Types

Vaccination can be regarded as one of biomedicines biggest triumphs. Since Edward Jenner pioneered the smallpox vaccine in 1798, subsequent morbidity and mortality rates have declined for a multitude of diseases, such as Diphtheria, Whooping Cough and Measles.1 However, despite the success of these global vaccination